TYRA - Company ID 0001863127
The table below shows Tyra Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$32.57M | -$25.46M | -$22.03M | -$9.85M | -$8.93M | -$4.68M |
| Capital expenditure | $88.00K | $14.00K | $136.00K | $41.00K | $239.00K | $60.00K |
| Investing cash flow | -$120.24M | $32.03M | $18.07M | -$41.00K | -$239.00K | -$60.00K |
| Dividends paid | - | - | - |
Tyra Biosciences, Inc. reported operating cash flow of -$95.14M for fiscal year 2025. That is down 36.4% from -$69.77M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$7.76M (FY 2020) to -$95.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $160.38M | $2.19M | $200.31M | $376.00K | $238.00K | $130.15M |